Aug 2026· Metabolism: Clinical and Experimental· pp.
156731
· 1 citation· 46 references
Medicine
TL;DR
Dysregulation of α-KG and L-2HG drives diabetic muscle fibrosis by disrupting TET2-dependent DNA hydroxymethylation and FAP division symmetry, supporting a TET2-dependent mechanism underlying the epigenetic effects of α-KG.
Abstract
Objective
Fibro-adipogenic progenitor (FAP) dysfunction drives skeletal muscle fibrosis in type 2 diabetes mellitus (T2DM), yet the underlying metabolic-epigenetic mechanisms remain poorly understood. This study investigates how metabolite fluctuations regulate the cell fate of CD90+ FAPs in the diabetic skeletal muscles.
Methods
AND
Results
Re-analysis of single-cell RNA sequencing data from human diabetic skeletal muscle, combined with immunofluorescence staining of biopsy specimens, revealed a significant expansion of CD90+ FAPs characterized by aberrant asymmetric cell division (ACD) associated polarity and a profibrotic phenotype. Using LC-MS, we identified a marked metabolic shift in insulin-resistant CD90+ FAPs, with reduced alpha-ketoglutarate (α-KG) and elevated L-2-hydroxyglutarate (L-2HG) levels. Reduced α-KG availability, together with competitive inhibition by accumulated L-2HG, suppresses TET2 activity and shifts DNA cytosine modification toward increased 5mC and decreased 5hmC. Specifically, epigenetic remodeling at the promoters of polarity-related genes-Pard3b, Pard6b, and Prkcz-was associated with activation of an ACD-related polarity program in CD90+ FAPs. This lineage bias promotes fibrogenic differentiation, ultimately exacerbating collagen accumulation and impairing muscle function. Dietary α-KG supplementation restored the α-KG/L-2HG ratio, restrained aberrant ACD-related polarity program, and effectively prevented or alleviated muscle fibrosis in T2DM mice. Conversely, TET2 knockdown attenuated the protective effects of α-KG on DNA hydroxymethylation and profibrotic activation of CD90+ FAPs, supporting a TET2-dependent mechanism underlying the epigenetic effects of α-KG.
Conclusion
Our findings demonstrate that dysregulation of α-KG and L-2HG drives diabetic muscle fibrosis by disrupting TET2-dependent DNA hydroxymethylation and FAP division symmetry. Restoring this metabolic-epigenetic axis represents a promising therapeutic strategy for treating diabetic skeletal muscle fibrosis.
It is shown that dysregulated endocrine function of skeletal muscle promotes bone loss through YAP1-driven pathogenic FAPs secreting IL-6 and FGF21, identifying FAP-derived IL-6 and FGF21 as key mediators of muscle-bone crosstalk and establishing the YAP-FAP-myokine axis as a therapeutic target for preventing bone loss...
Xiaoyu Cai, Tao Xu, R. Ma et al.· Advancement of science· 0 citations
It is demonstrated that diosgenin alleviates age‐related sarcopenia by activating the SIRT1/PGC‐1α signaling pathway to promote satellite cell proliferation and myogenic differentiation, highlighting its potential as a promising therapeutic candidate for sarcopenia.
Xin Zeng, Han-Wen Ding, Ziye Li et al.· Aging Cell· 0 citations
These findings demonstrate that UC-MSCs function as context-dependent metabolic modulators, alleviating oxidative stress-induced sarcopenia through attenuation of oxidative stress, restoration of systemic IGF-1, and selective reprogramming of lipid metabolism, while dynamically adjusting energy metabolism in physiologi...
This review describes T2DM pathogenesis through a novel spatial-bioenergetic-immune axis, stratifying disease progression across three hierarchical levels, and advocates for a transition toward precision clinical management of T2DM-associated sarcopenia, aimed at arresting skeletal muscle degeneration and preserving ph...
Ling-Feng Wu, Hong Ye, Xiao-Feng Wang et al.· Journal of Inflammation Rese...· 0 citations
A previously unrecognized HO-1–dependent pathway by which CBD dampens profibrotic activation in human DMD and control hiPSC-cFib is uncovered, highlighting its potential as a therapeutic approach to limit cardiac fibrosis in Duchenne muscular dystrophy.
L. Savchenko, S. Soussi, D. Rovina et al.· Redox Biology· 0 citations
It is demonstrated that TMZ mitigates dystrophic pathology by targeting the ATP6AP2 signaling axis and dampening macrophage-mediated inflammatory responses, highlighting its potential as a novel immunopharmacological therapeutic strategy for DMD.
Lin Zhou, Yu Zhang, Xinxin Tan et al.· International Immunopharmaco...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.